RAC1 and carcinoma: Therefore, it is possible to suggest that inhibiting Rac1 signaling in the detached carcinoma cells would combat anoikis resistance and thus result in cell death of the most treatment-resistant cells having increased metastatic activities, i.e. of the CSCs.